Assessment the efficacy of tranexamic acid for reduce melasma using MASI/mMASI score: A systematic review and meta-analysis of randomized controlled trials


  • Monica Trifitriana Sriwijaya University
  • Yuli Kurniawati Sriwijaya University
  • Rido Mulawarman Sriwijaya University


Tranexamic acid, Melasma, MASI/mMasi, Meta-analysis, Systematic Review


Background Melasma is a commonly acquired pigmentary disorder, appearing as brown macules and patches on sun-exposed areas of the face and neck. Many treatments have been attempted to reduce melasma, however no universally impact procedure to promising results. In recent studies, tranexamic acid (TXA) oral, injection, or topical has been used for treating/ reducing melasma with promising results. Tranexamic acid has main effect for skin as a whitening effect either systematically or topically preparation. We aim to to provide the latest evidence on the clinical efficacy of TXA in the treatment of melasma by pooling data from cohort studies.   Methods We performed a comprehensive search on topics that assesses tranexamic acid to reduce melasma from inception up until May 2023.   Results There were 21 studies out of a total of 1167 patients reported the changes of MASI/mMASI score after using oral, topical, and injection TXA at 4 weeks, 8 weeks, and 12 weeks. The pooled analysis showed the significantly of reduction in melasma area severity index/modified melasma area severity index (MASI/mMasi) scores at 4 weeks (MD: 3.58; 95% CI, 2.15-5.01;I2 = 92%), 8 weeks (MD: 5.08; 95% CI, 3.34–6.81;I2=96%) and 12 weeks (MD: 4.89; 95% CI, 3.80–5.97;I2=91%) after treatment were all less than the baseline scores, regardless of the delivery route.   Conclusion The objective of this thorough examination and analysis is to present the available information regarding the application of TXA as a treatment option for individuals with melasma. Additional extensive randomized controlled trials (RCTs) are required to determine the most effective dosage and treatment plan for TXA.  

Author Biographies

Yuli Kurniawati, Sriwijaya University

Dermatology and Venereology Department, Mohammad Hoesin Central General Hospital, Palembang

Rido Mulawarman, Sriwijaya University

Sriwijaya University, Faculty of Medicine, Palembang


Spierings NMK. Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years. J Cosmet Dermatol. 2020;19(6):1284-1289.

Sarkar R, Bansal A, Ailawadi P. Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol. 2020;86(1):8-17.

Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005-1032.

Chung JY, Lee JH, Lee JH. Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study. J Dermatolog Treat. 2016;27(4):373-377.

Taraz Mohammad, Niknam Somayeh, Ehsani Amir Houshang. Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. Dermatologic Therapy. 2017;30 (3):e12465

Khurana VK, Misri RR, Agarwal S, Thole AV, Kumar S, Anand T. A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma. Indian J Dermatol Venereol Leprol. 2019;85(1):39-43.

Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46(2):111-116.

Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016;41(5):480-485.




How to Cite

Trifitriana M, Kurniawati Y, Mulawarman R. Assessment the efficacy of tranexamic acid for reduce melasma using MASI/mMASI score: A systematic review and meta-analysis of randomized controlled trials. J Pak Assoc Dermatol [Internet]. 2024May6 [cited 2024May19];34(1):255-61. Available from:



Review Articles

Most read articles by the same author(s)